CMS approves Wash. state Medicaid payment model for Hepatitis C drugs

The Centers for Medicare & Medicaid Services yesterday approved a Medicaid state plan amendment allowing Washington state to negotiate supplemental rebate agreements with drug makers based on value. CMS has approved similar state plan amendments for Oklahoma, Michigan and Colorado, but this is the first to focus on Hepatitis C drugs. Specifically, it allows the state to negotiate under a subscription model to pay a fixed annual amount to purchase an unrestricted supply of Hepatitis C drugs.
Related News Articles
Headline
The AHA and other national hospital organizations Sept. 5 urged Senate and House leadership to act on preventing Medicaid Disproportionate Share Hospital…
Headline
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.“It is a ‘solution’ in search of a…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…